Reported Earlier, Dyne Therapeutics Prices Upsized $375M Public Offering Of 18.3M Common Shares At $20.50 Per Share
Share
Why It Matters
Dyne Therapeutics sold more shares of its company to raise money ($375 million) than it first planned. When a company does this, it means they need cash to keep growing and developing their medicine.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.